Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Lisata Therapeutics (LSTA) EBITDA (2016 - 2025)

Lisata Therapeutics filings provide 13 years of EBITDA readings, the most recent being -$3.1 million for Q4 2025.

  • For the quarter ending Q4 2025, EBITDA rose 37.79% year-over-year to -$3.1 million, compared with a TTM value of -$18.2 million through Dec 2025, up 18.75%, and an annual FY2025 reading of -$18.2 million, up 18.74% over the prior year.
  • EBITDA hit -$3.1 million in Q4 2025 for Lisata Therapeutics, up from -$4.4 million in the prior quarter.
  • The five-year high for EBITDA was -$3.1 million in Q4 2025, with the low at -$6.9 million in Q2 2023.
  • Median EBITDA over the past 3 years was -$5.7 million (2024), compared with a mean of -$5.5 million.
  • The sharpest move saw EBITDA grew 3.55% in 2024, then skyrocketed 37.79% in 2025.
  • Year by year, EBITDA stood at -$6.0 million in 2023, then grew by 17.86% to -$4.9 million in 2024, then soared by 37.79% to -$3.1 million in 2025.
  • According to Business Quant data, EBITDA over the past three periods came in at -$3.1 million, -$4.4 million, and -$4.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.